US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
DE69737413T2
(de)
|
1996-01-04 |
2007-10-31 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Bakterioferritin aus helicobacter pylori
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
EP0991403B1
(en)
|
1997-01-30 |
2003-04-02 |
Chiron Corporation |
Use of microparticles with adsorbed antigen to stimulate immune responses
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
CA2301575C
(en)
|
1997-05-20 |
2003-12-23 |
Ottawa Civic Hospital Loeb Research Institute |
Vectors and methods for immunization or therapeutic protocols
|
AU753172B2
(en)
|
1997-06-06 |
2002-10-10 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US7138384B1
(en)
|
1997-08-29 |
2006-11-21 |
The Regents Of The University Of California |
Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
CA2323929C
(en)
|
1998-04-03 |
2004-03-09 |
University Of Iowa Research Foundation |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
DK1079824T3
(da)
|
1998-05-19 |
2011-11-21 |
Res Dev Foundation |
Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf
|
DK1077722T3
(da)
|
1998-05-22 |
2006-11-27 |
Ottawa Health Research Inst |
Fremgangsmåder og produkter til induktion af mukosaimmunitet
|
EP1104306B1
(en)
|
1998-08-10 |
2006-01-11 |
Antigenics Inc. |
Compositions of cpg and saponin adjuvants and methods of use thereof
|
FR2783170B1
(fr)
*
|
1998-09-11 |
2004-07-16 |
Pasteur Merieux Serums Vacc |
Emulsion immunostimulante
|
US6887464B1
(en)
|
1999-02-02 |
2005-05-03 |
Biocache Pharmaceuticals, Inc. |
Advanced antigen presentation platform
|
WO2000045847A1
(en)
*
|
1999-02-05 |
2000-08-10 |
Alk-Abelló A/S |
Novel mucosal delivery system
|
ES2242604T3
(es)
|
1999-02-26 |
2005-11-16 |
Chiron Corporation |
Microemulsiones con macroparticulas y microparticulas adsorbidas.
|
JP4812942B2
(ja)
*
|
1999-02-26 |
2011-11-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
IL145982A0
(en)
|
1999-04-19 |
2002-07-25 |
Smithkline Beecham Biolog |
Vaccines
|
EP1177439B1
(en)
*
|
1999-04-29 |
2004-09-08 |
Coley Pharmaceutical GmbH |
Screening for immunostimulatory dna functional modifiers
|
BR0010323A
(pt)
*
|
1999-05-06 |
2002-01-08 |
Immune Response Corp Inc |
Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
|
US6737066B1
(en)
|
1999-05-06 |
2004-05-18 |
The Immune Response Corporation |
HIV immunogenic compositions and methods
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
US7479285B1
(en)
|
1999-08-19 |
2009-01-20 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
KR100737980B1
(ko)
*
|
1999-08-27 |
2007-07-12 |
아이넥스 파머슈티컬스 코포레이션 |
사이토카인 분비 자극용 및 면역반응 유도용 조성물
|
GB9921147D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
EP1700603A3
(en)
*
|
1999-09-25 |
2007-06-13 |
Coley Pharmaceutical GmbH |
Immunostimulatory nucleic acids
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
DE60131430T2
(de)
|
2000-01-14 |
2008-10-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
EP1950296B1
(en)
*
|
2000-01-14 |
2014-05-07 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
US20010044416A1
(en)
*
|
2000-01-20 |
2001-11-22 |
Mccluskie Michael J. |
Immunostimulatory nucleic acids for inducing a Th2 immune response
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
US20020107212A1
(en)
*
|
2000-03-10 |
2002-08-08 |
Nest Gary Van |
Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
|
US7157437B2
(en)
*
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US20020028784A1
(en)
*
|
2000-03-10 |
2002-03-07 |
Nest Gary Van |
Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
|
US20010046967A1
(en)
*
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
CA2407897A1
(en)
*
|
2000-05-05 |
2001-11-15 |
Cytos Biotechnology Ag |
Molecular antigen arrays and vaccines
|
DE60139689D1
(de)
*
|
2000-06-22 |
2009-10-08 |
Univ Iowa Res Found |
Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
|
US6943240B2
(en)
|
2000-09-15 |
2005-09-13 |
Coley Pharmaceuticals Gmbh |
Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
|
EP2284183A1
(en)
|
2000-10-27 |
2011-02-16 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic acids and proteins from streptococcus groups A and B
|
ES2307568T3
(es)
|
2000-12-08 |
2008-12-01 |
Coley Pharmaceutical Gmbh |
Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
|
NZ526322A
(en)
|
2000-12-27 |
2005-06-24 |
Dynavax Tech Corp |
Immunomodulatory polynucleotides and methods of using the same
|
US7094409B2
(en)
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
US7858588B2
(en)
|
2001-05-21 |
2010-12-28 |
Intercell Ag |
Immunostimulatory oligodeoxynucleic molecules
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
DK2423335T3
(da)
|
2001-06-21 |
2014-08-18 |
Dynavax Tech Corp |
Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
JP4607452B2
(ja)
|
2001-08-07 |
2011-01-05 |
ダイナバックス テクノロジーズ コーポレイション |
免疫調節性組成物、製剤およびその使用方法
|
CN1604795B
(zh)
|
2001-08-17 |
2010-05-26 |
科勒制药股份公司 |
具有提高的活性的组合基序免疫刺激寡肽
|
JP4319908B2
(ja)
|
2001-08-24 |
2009-08-26 |
ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション |
プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
|
CN1599623B
(zh)
|
2001-09-14 |
2011-05-11 |
赛托斯生物技术公司 |
免疫刺激物向病毒样颗粒内的包装:制备方法与用途
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
WO2003027313A2
(en)
|
2001-09-24 |
2003-04-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
JP2005508945A
(ja)
*
|
2001-10-06 |
2005-04-07 |
メリアル リミテッド |
Cpg配合物及び関連方法
|
EP1467755A1
(en)
|
2001-12-21 |
2004-10-20 |
Antigenics Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
AU2003203079B9
(en)
*
|
2002-02-04 |
2009-01-15 |
Oncothyreon Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
ES2607431T3
(es)
|
2002-02-20 |
2017-03-31 |
Glaxosmithkline Biologicals Sa |
Micropartículas con moléculas que contienen polipéptidos adsorbidos
|
BR0307975A
(pt)
|
2002-02-25 |
2005-01-11 |
Elan Pharm Inc |
Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
|
US7494655B2
(en)
|
2002-03-05 |
2009-02-24 |
Ramot At Tel-Aviv University Ltd. |
Immunizing composition and method for inducing an immune response against the β-secretase cleavage site of amyloid precursor protein
|
NZ573064A
(en)
|
2002-04-04 |
2011-02-25 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
DE60336902D1
(de)
|
2002-07-19 |
2011-06-09 |
Cytos Biotechnology Ag |
Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
|
AU2003254585A1
(en)
|
2002-07-24 |
2004-02-16 |
Intercell Ag |
Antigens encoded by alternative reading frame from pathogenic viruses
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
EP1537418A2
(en)
|
2002-09-13 |
2005-06-08 |
Intercell AG |
Method for isolating hepatitis c virus peptides
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
JP4697706B2
(ja)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
EP1562982B1
(en)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics S.r.l. |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004053104A2
(en)
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
SI1575977T1
(sl)
|
2002-12-23 |
2010-01-29 |
Dynavax Tech Corp |
Imunostimulirni sekvenčni polinukleotidi in postopki za njihovo uporabo
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
CA3042073C
(en)
|
2003-01-30 |
2022-09-13 |
Novartis Vaccines And Diagnostics S.R.L. |
Injectable vaccines against multiple meningococcal serogroups
|
EP1601756B1
(en)
|
2003-02-20 |
2010-12-15 |
University of Connecticut Health Center |
Methods for the preparation of alpha (2) macroglobulin-antigenic molecule complexes
|
AU2004224746B2
(en)
|
2003-03-24 |
2009-04-23 |
Valneva Austria Gmbh |
Improved vaccines
|
WO2004085635A1
(en)
|
2003-03-26 |
2004-10-07 |
Cytos Biotechnology Ag |
Melan-a peptide analogue-virus-like-particle conjugates
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ES2529736T3
(es)
|
2003-04-10 |
2015-02-25 |
Novartis Vaccines And Diagnostics, Inc. |
Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
EP2361928B1
(en)
|
2003-05-19 |
2017-04-26 |
Prothena Biosciences Limited |
Truncated fragments of alpha-synuclein in Lewy body disease
|
CA2528007C
(en)
|
2003-06-02 |
2012-03-27 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
US8541002B2
(en)
|
2003-09-12 |
2013-09-24 |
Agenus Inc. |
Vaccine for treatment and prevention of herpes simplex virus infection
|
JP4738339B2
(ja)
|
2003-10-02 |
2011-08-03 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
複数の髄膜炎菌血清群についての液体ワクチン
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1722815A1
(en)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza virus vaccines
|
US7820175B2
(en)
|
2004-03-19 |
2010-10-26 |
Herbal Spring, Llc |
Herbal therapy for the treatment of food allergy
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
EP1740217B1
(en)
|
2004-04-30 |
2011-06-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Meningococcal conjugate vaccination
|
AU2005247341B2
(en)
|
2004-05-06 |
2008-05-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP4896021B2
(ja)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
呼吸器系病原体ワクチンのためのアルファウイルスベクター
|
US20090317420A1
(en)
|
2004-07-29 |
2009-12-24 |
Chiron Corporation |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
US9573979B2
(en)
|
2004-09-24 |
2017-02-21 |
Susanne Modrow |
Modified VP1-capsid protein of parvovirus B19
|
CA2584859C
(en)
|
2004-10-25 |
2017-11-07 |
Merck & Co., Inc. |
Anti-addl antibodies and uses thereof
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0424563D0
(en)
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
CN100485034C
(zh)
*
|
2005-01-28 |
2009-05-06 |
权滢周 |
从分支杆菌中提取的用于刺激免疫功能,治疗免疫相关性疾病,过敏性皮炎和/或保护正常免疫细胞的寡核苷酸
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
NZ561042A
(en)
|
2005-02-18 |
2011-03-31 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
US8642577B2
(en)
|
2005-04-08 |
2014-02-04 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
SG175456A1
(en)
|
2005-04-18 |
2011-11-28 |
Novartis Vaccines & Diagnostic |
Expressing hepatitis b virus surface antigen for vaccine preparation
|
EP1891093B1
(en)
|
2005-06-14 |
2011-03-23 |
Protox Therapeutics Incorporated |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
|
PL2179737T3
(pl)
|
2005-07-01 |
2014-01-31 |
Index Pharmaceuticals Ab |
Sposób do modulowania wrażliwości na steroidy
|
EP2380584B1
(en)
|
2005-07-01 |
2013-10-16 |
Index Pharmaceuticals AB |
Immunostimulatory method
|
EP1909564A4
(en)
|
2005-07-18 |
2010-06-30 |
Novartis Ag |
SMALL ANIMAL MODEL FOR HCV REPLICATION
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
AU2006306805A1
(en)
|
2005-10-28 |
2007-05-03 |
Index Pharmaceuticals Ab |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
US10842867B2
(en)
|
2005-11-04 |
2020-11-24 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
AU2006310163B2
(en)
|
2005-11-04 |
2011-09-15 |
Seqirus UK Limited |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
NZ567979A
(en)
|
2005-11-04 |
2012-02-24 |
Novartis Vaccines & Diagnostic |
Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
|
WO2007052058A1
(en)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
BRPI0707300B8
(pt)
|
2006-01-27 |
2021-05-25 |
Novartis Ag |
vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
|
CN106237316A
(zh)
|
2006-03-07 |
2016-12-21 |
法克斯因内特公司 |
包含血细胞凝集素的组合物、制造其的方法与使用其的方法
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
CA2647942A1
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
WO2007119815A1
(ja)
|
2006-04-14 |
2007-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
Toll様受容体9作動薬
|
JP2009538924A
(ja)
|
2006-06-01 |
2009-11-12 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Appの神経活性断片
|
EP2035035A2
(en)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Immunogenic compositions for streptococcus agalactiae
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
MX2009002408A
(es)
|
2006-09-11 |
2009-03-20 |
Novartis Ag |
Elaboracion de vacunas para el virus de la influenza sin utilizar huevos.
|
EP2121011B1
(en)
|
2006-12-06 |
2014-05-21 |
Novartis AG |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
JP5558834B2
(ja)
|
2007-02-23 |
2014-07-23 |
ヤンセン アルツハイマー イミュノセラピー |
シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置
|
HUE043966T2
(hu)
|
2007-02-23 |
2019-09-30 |
Prothena Biosciences Ltd |
Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
MX2010002773A
(es)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Antigenos mutantes de gas57 y anticuerpos de gas57.
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
ES2664753T3
(es)
|
2007-12-07 |
2018-04-23 |
Glaxosmithkline Biologicals Sa |
Composiciones de inducción de respuestas inmunes
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
CA2710984C
(en)
|
2007-12-28 |
2018-05-29 |
Elan Pharmaceuticals, Inc. |
Treatment and prophylaxis of amyloidosis
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
CA2718430A1
(en)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Improvements in preparation of influenza virus vaccine antigens
|
AU2009236585B2
(en)
|
2008-04-18 |
2013-03-07 |
Vaxinnate Corporation |
Deletion mutants of flagellin and methods of use
|
EP2278979A4
(en)
|
2008-05-21 |
2012-09-26 |
Us Gov Health & Human Serv |
PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODESOXYNUCLEOTIDES
|
US8580280B2
(en)
|
2008-06-27 |
2013-11-12 |
Zoetis Llc |
Adjuvant compositions
|
EP2331127A2
(en)
|
2008-09-18 |
2011-06-15 |
Novartis AG |
Vaccine adjuvant combinations
|
AU2009325950B2
(en)
|
2008-12-09 |
2013-03-07 |
Pfizer Vaccines Llc |
IgE CH3 peptide vaccine
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
EA201500910A1
(ru)
|
2009-02-10 |
2016-04-29 |
Новартис Аг |
Вакцины против гриппа со сниженным количеством сквалена
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
JP5597245B2
(ja)
|
2009-03-24 |
2014-10-01 |
ノバルティス アーゲー |
アジュバント添加した髄膜炎菌h因子結合タンパク質
|
RU2015117604A
(ru)
|
2009-04-03 |
2015-10-27 |
Эйдженус Инк. |
Способы получения и применения мультишаперон-антигенных комплексов
|
DK2510947T3
(da)
|
2009-04-14 |
2016-03-21 |
Glaxosmithkline Biolog Sa |
Sammensætninger til immunisering mod Staphylococcus aureus.
|
AU2010254551B2
(en)
|
2009-05-27 |
2016-10-20 |
Selecta Biosciences, Inc. |
Immunomodulatory agent-polymeric compounds
|
CN102802665B
(zh)
|
2009-06-15 |
2015-11-25 |
新加坡国立大学 |
流感疫苗、组合物及使用方法
|
ES2563730T3
(es)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
|
DK2464658T3
(da)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoksificerede escherichia coli-immunogener
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
WO2011024071A1
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Adjuvant comprising aluminium, oligonucleotide and polycation
|
US20110076300A1
(en)
|
2009-08-27 |
2011-03-31 |
Mariagrazia Pizza |
Hybrid Polypeptides Including Meningococcal fHBP Sequences
|
CA2771770A1
(en)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
WO2011030218A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
EP2483390A2
(en)
|
2009-09-30 |
2012-08-08 |
Novartis AG |
Expression of meningococcal fhbp polypeptides
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
CA2785585A1
(en)
|
2009-12-22 |
2011-06-30 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
EP2534150B1
(en)
|
2010-02-12 |
2017-04-05 |
Chimerix, Inc. |
Methods of treating viral infection
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
US20130071422A1
(en)
|
2010-03-18 |
2013-03-21 |
Michele Pallaoro |
Adjuvanted vaccines for serogroup b meningococcus
|
BR122021020829B8
(pt)
|
2010-03-30 |
2022-12-27 |
Children´S Hospital & Res Center At Oakland |
Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2556151A1
(en)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Method for generating a parvovirus b19 virus-like particle
|
CA2796314A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
CA2798323A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Dose selection of adjuvanted synthetic nanocarriers
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
EP2585106A1
(en)
|
2010-06-25 |
2013-05-01 |
Novartis AG |
Combinations of meningococcal factor h binding proteins
|
MX2013000163A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Metodos y composiciones inmunogenicas derivadas de norovirus.
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
WO2012009442A2
(en)
|
2010-07-14 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
Anti-addl monoclonal antibody and uses thereof
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
US9994443B2
(en)
|
2010-11-05 |
2018-06-12 |
Selecta Biosciences, Inc. |
Modified nicotinic compounds and related methods
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2655389A2
(en)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Compounds
|
DK2667892T3
(da)
|
2011-01-26 |
2019-05-13 |
Glaxosmithkline Biologicals Sa |
RSV-vaccineringsprogram
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
RU2754446C2
(ru)
|
2011-04-22 |
2021-09-02 |
ВАЙЕТ ЭлЭлСи |
Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
|
HUE034673T2
(en)
|
2011-05-13 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Pre-fusion Rsv F antigens
|
JP6093759B2
(ja)
|
2011-06-01 |
2017-03-08 |
ジャナス バイオセラピューティクス,インク. |
新規の免疫系調節剤
|
AU2012262021B2
(en)
|
2011-06-01 |
2016-07-28 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
ES2656050T3
(es)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinación inmunogénica y usos de las mismas
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
ES2687129T3
(es)
|
2011-07-25 |
2018-10-23 |
Glaxosmithkline Biologicals Sa |
Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
|
US20130028857A1
(en)
|
2011-07-29 |
2013-01-31 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
US9511130B2
(en)
|
2011-09-14 |
2016-12-06 |
Glaxosmithkline Biologicals Sa |
Escherichia coli vaccine combination
|
US9873694B2
(en)
|
2011-10-04 |
2018-01-23 |
Janus Biotherapeutics, Inc. |
Imidazole quinoline-based immune system modulators
|
CA2854934A1
(en)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
WO2013084071A2
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
CN113813294A
(zh)
|
2012-01-16 |
2021-12-21 |
E·麦肯纳 |
用于治疗肝脏疾病和障碍的组合物和方法
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
WO2013124473A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
EP2841098A4
(en)
|
2012-04-23 |
2016-03-02 |
Allertein Therapeutics Llc |
NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP3804749A3
(en)
|
2012-04-26 |
2021-07-28 |
GlaxoSmithKline Biologicals S.A. |
Antigens and antigen combinations
|
MX359257B
(es)
|
2012-05-04 |
2018-09-19 |
Pfizer |
Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
|
ES2820898T3
(es)
|
2012-05-22 |
2021-04-22 |
Glaxosmithkline Biologicals Sa |
Conjugado del serogrupo X de meningococos
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
EP4056198A3
(en)
|
2012-09-18 |
2022-12-07 |
GlaxoSmithKline Biologicals SA |
Outer membrane vesicles
|
EP2898073A4
(en)
*
|
2012-09-21 |
2016-03-23 |
Elizabeth Mckenna |
Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof
|
WO2014053612A1
(en)
|
2012-10-03 |
2014-04-10 |
Novartis Ag |
Immunogenic composition
|
BR122016023101B1
(pt)
|
2012-10-21 |
2022-03-22 |
Pfizer Inc |
Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
|
CA2900008A1
(en)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
AU2014248515B2
(en)
|
2013-03-13 |
2019-03-07 |
Prothena Biosciences Limited |
Tau immunotherapy
|
MX2015013894A
(es)
|
2013-04-03 |
2015-12-11 |
Allertein Therapeutics Llc |
Composiciones de nanoparticulas novedosas.
|
US20210145963A9
(en)
|
2013-05-15 |
2021-05-20 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
EP3033106A1
(en)
*
|
2013-08-14 |
2016-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunoadjuvant compositions and uses thereof
|
UA121200C2
(uk)
|
2013-09-19 |
2020-04-27 |
Зоетіс Сервісіз Ллс |
Ад'ювант на основі олії
|
SG10201910889VA
(en)
|
2013-11-01 |
2020-01-30 |
Pfizer |
Vectors for expression of prostate-associated antigens
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
US11191832B2
(en)
|
2013-11-19 |
2021-12-07 |
Prothena Biosciences Limited |
Monitoring immunotherapy of Lewy body disease from constipation symptoms
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
KR20160127825A
(ko)
|
2014-03-12 |
2016-11-04 |
프로테나 바이오사이언시즈 리미티드 |
항-mcam 항체 및 관련된 사용 방법
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
BR112016022011A2
(pt)
|
2014-03-26 |
2017-10-24 |
Glaxosmithkline Biologicals Sa |
?antígeno de proteína estafilocócica a mutante, proteína de fusão, e, composição imunogênica?
|
US20170275287A1
(en)
|
2014-08-22 |
2017-09-28 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
KR102508719B1
(ko)
|
2015-01-16 |
2023-03-09 |
조에티스 서비시즈 엘엘씨 |
구제역 백신
|
AU2016260540B2
(en)
|
2015-05-13 |
2021-01-07 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
AU2016281904B2
(en)
|
2015-06-26 |
2022-08-11 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
CA2998716A1
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
PL3405212T3
(pl)
|
2016-01-19 |
2020-11-16 |
Pfizer Inc. |
Szczepionki przeciwnowotworowe
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
EA201892417A1
(ru)
|
2016-05-02 |
2019-05-31 |
Протена Биосайенсис Лимитед |
Антитела, распознающие тау
|
EP3452507B1
(en)
|
2016-05-02 |
2022-10-19 |
Prothena Biosciences Limited |
Tau immunotherapy
|
KR20230070336A
(ko)
|
2016-05-02 |
2023-05-22 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
AU2018263935A1
(en)
|
2017-05-02 |
2019-12-19 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
KR102625114B1
(ko)
|
2017-09-28 |
2024-01-12 |
화이자 인코포레이티드 |
클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
JP2022524588A
(ja)
|
2019-03-03 |
2022-05-09 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
US20220160859A1
(en)
|
2019-04-01 |
2022-05-26 |
Pfizer Inc. |
Compositions and methods for eliciting an immune response against clostridium difficile
|
EP4168032A2
(en)
|
2020-06-19 |
2023-04-26 |
Pfizer Inc. |
Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
WO2022196701A1
(ja)
|
2021-03-16 |
2022-09-22 |
国立大学法人大阪大学 |
濾胞性t細胞を用いた新規医療技術
|
EP4310095A1
(en)
|
2021-03-16 |
2024-01-24 |
Osaka University |
Follicular helper t (tfh) cells specific to sars-cov-2 virus
|
WO2023201109A1
(en)
|
2022-04-15 |
2023-10-19 |
Yale University |
Exatecan formulation
|